Q Therapeutics' ALS candidate gets orphan status from FDA

11/19/2013 | Salt Lake Tribune (Utah), The

The FDA granted orphan-drug status to Q Therapeutics' experimental drug Q-Cells as a treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease. The designation will give the stem cell drug developer several incentives such as tax credits and seven years of market exclusivity.

View Full Article in:

Salt Lake Tribune (Utah), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX